Laurus Labs: The financial results for the period ended September 30, 2026
Laurus Labs (LAURUSLABS) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹1.2 lakh crore.
What happened
Laurus Labs (LAURUSLABS) filed a disclosure with the exchanges on 29 October 2026 at 02:55 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Laurus Labs is a large-cap company in the Healthcare sector, with a market value of about ₹1.2 lakh crore.
The stock last traded at ₹2,229, against a 52-week range of ₹918–₹2,143.1 (4.0% above the high).
Before this filing the shares had moved +6.7% over the month and +20.3% over three months. Average daily turnover over the last 20 sessions was about ₹308 crore.
Promoters held 27.47% at the end of Q1 FY27, down 0.02% points from the previous quarter; 2.69% of promoter shares were pledged. Foreign institutions owned 28.00% and domestic institutions 13.74%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,570 | 163 | 3.02 |
| Q2 FY26 | 3,223 | 358 | 6.63 |
| Q3 FY26 | 1,778 | 251.7 | 4.67 |
| Q4 FY26 | 1,812 | 279.1 | 5.17 |
| Q1 FY27 | 2,026 | 367.6 | 6.81 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.8% over five days; 55% of them rose the next day.
Market-wide, 9,836 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 29 October 2026: Board meeting — Financial Results/Dividend.
In the news
Recent coverage elsewhere (links open the original publisher):
- Laurus Labs Limited (LAURUSLABS.NS) Stock Price, News, Quote & History
- Laurus Labs to invest Rs 450 cr to expand its capacity this fiscal
- Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
- LAURUSLABS Outlook for the Week
- Laurus Labs zooms 128% from March low; hits new high in weak market
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.